Oral anticoagulant-proton pump inhibitor interactions: A pharmacovigilance assessment using disproportionality and interaction analyses

ABSTRACT

Objective: Oral anticoagulants operate within a narrow therapeutic window, with upper gastrointestinal bleeding representing a significant safety concern. While proton pump inhibitors (PPIs) have demonstrated gastroprotective properties, existing literature presents conflicting evidence regarding their interactions with oral anticoagulants. Methods: A detailed analysis was conducted using the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database. The study examined interactions between five oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban) and six PPIs (lansoprazole, dexlansoprazole, omeprazole, esomeprazole, pantoprazole, and rabeprazole). A case-non-case disproportionality analysis was employed, utilizing both frequentist and Bayesian data mining algorithms. Interaction Signal Scores were calculated to evaluate interaction strengths. Results: Of 29,163,222 initial reports, 5,222 met inclusion criteria. Significant interactions were identified across multiple anticoagulant-PPI combinations. Notably, dabigatran combined with omeprazole or pantoprazole, and apixaban with most PPIs, demonstrated increased hemorrhagic event risks. Gastrointestinal hemorrhage interactions were most extensive, with significant signals across multiple drug combinations. Certain combinations, like rivaroxaban-esomeprazole, showed protective effects, while others, such as rivaroxaban-rabeprazole, exhibited increased venous thromboembolic event risks. Conclusion: This pharmacovigilance analysis reveals complex interactions between oral anticoagulants and PPIs, highlighting the need for individualized risk assessment. Healthcare providers should carefully monitor patients receiving these combinations, considering potential hemorrhagic complications and patient-specific risk factors.

KEYWORDS

• Warfarin
• Dabigatran
• Rivaroxaban
• Apixaban
• Omeprazole
• Esomeprazole

Showing references and in-text citations exactly as published.

• DOI10.18549/PharmPract.2025.4.3326Copy

RELATED ARTICLES

Matched on section and article type within this issue of PP.

• Article · VOLUME 23, ISSUE 4Quercetin encapsulated polymeric nanomicelles substantially chemosensitising antiproliferation by branched chain amino acids with enhanced antiinflammation capacities: A new strategy against adherent cancer monolayersViolet Kasabri, Suhair Sunoqrot, Rasha Al-Motassem, Yusuf Al-Hiari, Riad Ababneh, Balqis Ikhmais, Hamza AbuMansour, Dalya Al-Saad, Dana Shalabi, Rema Alkhateeb · pp. 1–10Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4Conservation of Medicinal plants by sustainable aquaponics approach for novel drug developmentRamya Manoharan, Chythra Somanathan Nair, Drishya Nishanth, Radhakrishnan Subramanian, Xiulan Xie, Maozhi Ren, Abdul Jaleel · pp. 1–16Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4Fostering empathy and social responsibility in pharmacy students through experiential service-learning: A qualitative studySabeena Salam, Semira Beshir, Sadaf Sana, Faizah Hussain, Aliasgar Shahiwala · pp. 1–8Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4An investigative assessment on the quality of community pharmacy practice in the United Arab Emirates using common cold scenarioSubish Palaian, Muaed Alomar, Nageeb Hassan, Mukhtar Ansari · pp. 1–8Original ResearchSame type: Article